Here are the 10-Q quarterly reports from Kestra Medical Technologies, Ltd. (KMTS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KMTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KMTS filings page.
Kestra Medical Technologies (KMTS) reported strong top-line growth for the quarter ended July 31, 2026, with revenue of $31.0 million, up 60% from $19.4 million a year earlier, driven by more patients using its ASSURE wearable cardioverter defibrillator system. Gross profit nearly doubled to $17.5 million as cost per patient declined due to better equipment utilization and manufacturing efficiencies. Operating expenses rose sharply, with research and development at $6.8 million and selling, general and administrative at $48.4 million, contributing to a wider net loss of $44.1 million versus $25.8 million. Kestra ended the quarter with $244.7 million in cash, cash equivalents and investments and $72.5 million of long-term debt after drawing a new $75 million term loan and extinguishing its prior facility, which generated a $6.3 million loss on debt extinguishment. Management states that existing liquidity is expected to fund operations and capital needs for at least the next 12 months, while acknowledging potential future funding needs if growth investments or cash burn exceed expectations.
Kestra Medical Technologies reported strong top-line growth but wider losses as it scales its cardiac recovery platform. Revenue for the quarter ended January 31, 2026 rose to $24.6 million from $15.1 million, with gross profit nearly doubling to $12.9 million.
Nine‑month revenue increased to $66.5 million from $42.6 million, but higher research and development and especially selling, general and administrative expenses drove a quarterly net loss of $34.2 million and a nine‑month net loss of $92.8 million. Cash and cash equivalents were $291.3 million, supported by IPO proceeds and a December 2025 equity offering of 6.9 million shares that raised $149.3 million net. The company believes this liquidity will fund operations and capital needs for at least 12 months, while noting it may pursue additional financing to support growth.